Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 7279818, 8 pages
https://doi.org/10.1155/2017/7279818
Review Article

Psoriasis and Cardiovascular Risk—Do Promising New Biomarkers Have Clinical Impact?

1Clinic of Dermatology, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia
2Clinic of Dermatology, Tartu University Hospital, 31 Raja St., 50417 Tartu, Estonia
3Institute of Biomedicine and Translational Medicine, Department of Biochemistry, The Centre of Excellence for Genomics and Translational Medicine, University of Tartu, 19 Ravila St., 50411 Tartu, Estonia

Correspondence should be addressed to Sirje Kaur; ee.mukiniilk@ruak.ejris

Received 18 May 2017; Revised 1 August 2017; Accepted 7 August 2017; Published 29 August 2017

Academic Editor: Anna Balato

Copyright © 2017 Sirje Kaur et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. N. Mehta and J. M. Gelfand, “High density lipoprotein cholesterol function improves after successful treatment of psoriasis: a step forward in the right direction,” Journal of the American Academy of Dermatology, vol. 134, no. 3, pp. 592–595, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Ghazizadeh, H. Shimizu, M. Tosa, and M. Ghazizadeh, “Pathogenic mechanisms shared between psoriasis and cardiovascular disease,” International Journal of Medical Sciences, vol. 7, no. 5, pp. 284–289, 2010. View at Google Scholar
  3. W.-H. Boehncke and S. Boehncke, “Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives,” Current Rheumatology Reports, vol. 14, no. 4, pp. 343–348, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. G. A. Bonaterra, S. Zügel, and R. Kinscherf, “Novel systemic cardiovascular disease biomarkers,” Current Molecular Medicine, vol. 10, no. 2, pp. 180–205, 2010. View at Google Scholar
  5. L. Mallbris, O. Akre, F. Granath et al., “Increased cardiovascular mortality in psoriasis inpatients but not in outpatients,” European Journal of Epidemiology, vol. 19, no. 3, pp. 225–230, 2004. View at Google Scholar
  6. J. M. Gelfand, A. L. Neimann, D. B. Shin, X. Wang, D. J. Margolis, and A. B. Troxel, “Risk of myocardial infarction in patients with psoriasis,” The Journal of the American Medical Association, vol. 296, no. 14, pp. 1735–1741, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Takahashi and H. Iizuka, “Psoriasis and metabolic syndrome,” The Journal of Dermatology, vol. 39, no. 3, pp. 212–218, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Pietrzak, J. Bartosińska, G. Chodorowska, J. C. Szepietowski, P. Paluszkiewicz, and R. A. Schwartz, “Cardiovascular aspects of psoriasis: an updated review,” International Journal of Dermatology, vol. 52, no. 2, pp. 153–162, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Yeung, J. Takeshita, N. N. Mehta et al., “Psoriasis severity and the prevalence of major medical comorbidity: a population-based study,” JAMA Dermatology, vol. 149, no. 10, pp. 1173–1179, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. A. L. Neimann, D. B. Shin, X. Wang, D. J. Margolis, A. B. Troxel, and J. M. Gelfand, “Prevalence of cardiovascular risk factors in patients with psoriasis,” Journal of the American Academy of Dermatology, vol. 55, no. 5, pp. 829–835, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Wakkee, H. B. Thio, E. P. Prens, E. J. G. Sijbrands, and H. A. M. Neumann, “Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients,” Atherosclerosis, vol. 190, no. 1, pp. 1–9, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. W. Sterry, B. E. Strober, and A. Menter, “Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review,” The British Journal of Dermatology, vol. 157, no. 4, pp. 649–655, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Versini, P. Y. Jeandel, E. Rosenthal, and Y. Shoenfeld, “Obesity in autoimmune diseases: not a passive bystander,” Autoimmunity Reviews, vol. 13, no. 9, pp. 981–1000, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Gisondi, M. D. Giglio, and G. Girolomoni, “Considerations for systemic treatment of psoriasis in obese patients,” American Journal of Clinical Dermatology, vol. 17, no. 6, pp. 609–615, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Wolk, L. Mallbris, P. Larsson, A. Rosenblad, E. Vingård, and M. Ståhle, “Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis,” Acta Dermato-Venereologica, vol. 89, no. 5, pp. 492–497, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. A. W. Armstrong, C. T. Harskamp, and E. J. Armstrong, “The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies,” Nutrition & Diabetes, vol. 2, article e54, pp. 1–6, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. S. M. Langan, N. M. Seminara, D. B. Shin et al., “Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom,” The Journal of Investigative Dermatology, vol. 132, no. 3, pp. 556–562, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Ni and M. W. Chiu, “Psoriasis and comorbidities: links and risks,” Clinical, Cosmetic and Investigational Dermatology, vol. 17, no. 7, pp. 119–132, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Uczniak, Z. A. Gerlicz, M. Kozłowska, and A. Kaszuba, “Presence of selected metabolic syndrome components in patients with psoriasis vulgaris,” Advances in Dermatology and Allergology, vol. 33, no. 2, pp. 114–119, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Boehncke and W. H. Boehncke, “‘Upgrading’ psoriasis responsibly,” Experimental Dermatology, vol. 23, no. 10, pp. 710-711, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. C. M. Steyers and F. J. Miller, “Endothelial dysfunction in chronic inflammatory diseases,” International Journal of Molecular Sciences, vol. 15, no. 7, pp. 11324–11349, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. I. Roifman, P. L. Beck, M. J. Eisenberg, and J. Genest, “Chronic inflammatory diseases and cardiovascular risk: a systematic review,” The Canadian Journal of Cardiology, vol. 27, no. 2, pp. 174–182, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Takeshita, S. Grewal, S. M. Langan et al., “Psoriasis and comorbid diseases: implications for treatment,” Journal of the American Academy of Dermatology, vol. 76, no. 3, pp. 393–403, 2017. View at Google Scholar
  24. K. Abuabara, R. S. Azfar, D. B. Shin, A. L. Neimann, A. B. Troxel, and J. M. Gelfand, “Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K,” The British Journal of Dermatology, vol. 163, no. 3, pp. 586–590, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. N. N. Mehta, Y. Yu, R. Pinnelas et al., “Attributable risk estimate of severe psoriasis on major cardiovascular events,” The American Journal of Medicine, vol. 124, no. 8, pp. e1–e6, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Reich, “The concept of psoriasis as a systemic inflammation: implications of disease management,” Journal of the European Academy of Dermatology and Venereology, vol. 26, Supplement 2, pp. 3–11, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Lubrano, F. Cantini, A. Costanzo et al., “Measuring psoriatic disease in clinical practice. An expert opinion position paper,” Autoimmunity Reviews, vol. 14, no. 10, pp. 864–874, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Gerdes, S. Osadtschy, N. Buhles, H. Baurecht, and U. Mrowietz, “Cardiovascular biomarkers in patients with psoriasis,” Experimental Dermatology, vol. 2014, no. 23, pp. 322–325, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Tonel and C. Conrad, “Interplay between keratinocytes and immune cells—recent insights into psoriasis pathogenesis,” The International Journal of Biochemistry & Cell Biology, vol. 41, no. 5, pp. 963–968, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. S. P. Commins, L. Borish, and J. W. Steinke, “Immunologic messenger molecules: cytokines, interferons, and chemokines,” The Journal of Allergy and Clinical Immunology, vol. 125, Supplement 2, pp. S53–S72, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. J. B. Golden, T. S. McCormick, and N. L. Ward, “IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities,” Cytokine, vol. 62, no. 2, pp. 195–201, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Buske-Kirschbaum, S. Kern, M. Ebrecht, and D. H. Hellhammer, “Altered distribution of leukocyte subsets and cytokine production in response to acute psychological stress in patients with psoriasis vulgaris,” Brain, Behavior, and Immunity, vol. 21, no. 1, pp. 92–99, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. R. Heidenreich, M. Röcken, and K. Ghoreschi, “Angiogenesis drives psoriasis pathogenesis,” International Journal of Experimental Pathology, vol. 90, no. 3, pp. 232–248, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Wolk and R. Sabat, “Adipokines in psoriasis: an important link between skin inflammation and metabolic alterations,” Reviews in Endocrine & Metabolic Disorders, vol. 17, no. 3, pp. 305–317, 2016. View at Publisher · View at Google Scholar · View at Scopus
  35. C. E. Griffiths and J. N. Barker, “Pathogenesis and clinical features of psoriasis,” Lancet, vol. 370, no. 9583, pp. 263–271, 2007. View at Google Scholar
  36. B. J. Nickoloff, H. Xin, F. O. Nestle, and J. Z. Qin, “The cytokine and chemokine network in psoriasis,” Clinics in Dermatology, vol. 25, no. 6, pp. 568–573, 2007. View at Google Scholar
  37. R. C. Li, P. Krishnamoorthy, S. DerOhannessian et al., “Psoriasis is associated with decreased plasma adiponectin levels independently of cardiometabolic risk factors,” Clinical and Experimental Dermatology, vol. 39, no. 1, pp. 19–24, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Tilg and A. R. Moschen, “Adipocytokines: mediators linking adipose tissue, inflammation and immunity,” Nature Reviews Immunology, vol. 6, no. 10, pp. 772–783, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. A. T. Pietrzak, A. Zalewska, G. Chodorowska et al., “Cytokines and anticytokines in psoriasis,” Clinica Chimica Acta, vol. 394, no. 1-2, pp. 7–21, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. B. Strober, C. Teller, P. Yamauchi et al., “Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis,” The British Journal of Dermatology, vol. 159, no. 2, pp. 322–330, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Furukawa, T. Fujita, M. Shimabukuro et al., “Increased oxidative stress in obesity and its impact on metabolic syndrome,” The Journal of Clinical Investigation, vol. 114, no. 12, pp. 1752–1761, 2004. View at Google Scholar
  42. P. Holvoet, D. H. Lee, M. Steffers, M. Gross, and D. R. Jacobs, “Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome,” The Journal of the American Medical Association, vol. 299, no. 19, pp. 2287–2293, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Baran, I. Flisiak, J. Jaroszewicz, and M. Swiderska, “Effect of psoriasis activity on serum adiponectin and leptin levels,” Postepy Dermatologii i Alergologii, vol. 32, no. 2, pp. 101–106, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Vachatova, C. Andrys, J. Krejsek et al., “Metabolic syndrome and selective inflammatory markers in psoriatic patients,” Journal of Immunology Research, vol. 2016, Article ID 5380792, 8 pages, 2016. View at Publisher · View at Google Scholar
  45. P. M. Ridker, “A test in context: high-sensitivity C-reactive protein,” Journal of the American College of Cardiology, vol. 67, no. 6, pp. 712–723, 2016. View at Publisher · View at Google Scholar · View at Scopus
  46. P. Rocha-Pereira, A. Santos-Silva, I. Rebelo, A. Figueiredo, A. Quintanilha, and F. Teixeria, “The inflammatory response in mild and in severe psoriasis,” The British Journal of Dermatology, vol. 150, no. 5, pp. 917–928, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. A. B. Kimball and Y. Wu, “Cardiovascular disease and classic cardiovascular risk factors in patients with psoriasis,” International Journal of Dermatology, vol. 48, no. 11, pp. 1147–1156, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. D. G. Federman, M. Shelling, S. Prodanovich, C. G. Gunderson, and R. S. Kirsner, “Psoriasis: an opportunity to identify cardiovascular risk,” The British Journal of Dermatology, vol. 160, no. 1, pp. 1–7, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. H. Takahashi, H. Tsuji, Y. Hashimoto, A. Ishida-Yamamoto, and H. Iizuka, “Serum cytokines and growth factor levels in Japanese patients with psoriasis,” Clinical and Experimental Dermatology, vol. 35, no. 6, pp. 645–649, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Kaur, K. Zilmer, V. Leping, and M. Zilmer, “The levels of adiponectin and leptin and their relation to other markers of cardiovascular risk in patients with psoriasis,” Journal of the European Academy of Dermatology and Venereology, vol. 25, no. 11, pp. 1328–1333, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. G. Chodorowska, D. Wojnowska, and M. Juszkiewicz-Borowiec, “C-reactive protein and α2-macroglobulin plasma activity in medium-severe and severe psoriasis,” Journal of the European Academy of Dermatology and Venereology, vol. 18, no. 2, pp. 180–183, 2004. View at Publisher · View at Google Scholar
  52. S. Coimbra, H. Oliveira, F. Reis et al., “C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy,” Journal of the European Academy of Dermatology and Venereology, vol. 24, no. 7, pp. 789–796, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Mastroianni, E. Minutilli, A. Mussi et al., “Cytokine profiles during infliximab monotherapy in psoriatic arthritis,” The British Journal of Dermatology, vol. 153, no. 3, pp. 531–536, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Coimbra, H. Oliveira, F. Reis et al., “Circulating levels of adiponectin, oxidized LDL, and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease,” Journal of Dermatological Science, vol. 55, no. 3, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Coimbra, H. Oliveira, F. Reis et al., “Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy,” Journal of the European Academy of Dermatology and Venereology, vol. 24, no. 12, pp. 1386–1394, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. J. Deeva, S. Mariani, C. De Luca et al., “Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic disease,” Cytokine, vol. 49, no. 2, pp. 163–170, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Kaur, K. Zilmer, V. Leping, and M. Zilmer, “Comparative study of systemic inflammatory responses in psoriasis vulgaris and mild-to-moderate allergic contact dermatitis,” Dermatology, vol. 225, no. 1, pp. 54–61, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. S. Coimbra, H. Oliveira, F. Reis et al., “Psoriasis therapy and cardiovascular risk factors,” American Journal of Clinical Dermatology, vol. 11, no. 6, pp. 423–432, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Coimbra, H. Oliveira, F. Reis et al., “Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumor necrosis factor-α levels in patients with psoriasis before, during and after psoralen-ultraviolet A, and narrowband ultraviolet B therapy,” The British Journal of Dermatology, vol. 163, no. 6, pp. 1282–1290, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. N. Ouchi, J. L. Parker, J. J. Lugus, and K. Walsh, “Adipokines in inflammation and metabolic disease,” Nature Reviews Immunology, vol. 11, no. 2, pp. 85–97, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Blüher, “Adipose tissue dysfunction in obesity,” Experimental and Clinical Endocrinology & Diabetes, vol. 117, no. 6, pp. 241–250, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. A. M. J. Wassink, J. K. Olijhoek, and F. L. J. Visseren, “The metabolic syndrome: metabolic changes with vascular consequences,” European Journal of Clinical Investigation, vol. 37, no. 1, pp. 8–17, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. K. Marinou, D. Tousoulis, A. S. Antonopoulos, E. Stefanadi, and C. Stefanadis, “Obesity and cardiovascular disease: from pathophysiology to risk stratification,” International Journal of Cardiology, vol. 138, no. 1, pp. 3–8, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. S. Nakanishi, K. Yamane, N. Kamei, H. Nojima, M. Okubo, and N. Kohno, “A protective effect of adiponectin against oxidative stress in Japanese Americans: the association between adiponectin or leptin and urinary isoprostane,” Metabolism, vol. 54, no. 2, pp. 194–199, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. S. Störk, M. L. Bots, P. Angerer et al., “Low levels of adiponectin predicts worsening of arterial morphology and function,” Atherosclerosis, vol. 194, no. 2, pp. e147–e153, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. R. Wolk, P. Berger, R. J. Lennon, E. S. Brilakis, D. E. Davison, and V. K. Somers, “Association between plasma adiponectin levels and unstable coronary syndrome,” European Heart Journal, vol. 28, no. 3, pp. 292–298, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. D. H. Kim, C. Kim, E. L. Ding, M. K. Townsend, and L. A. Lipsitz, “Adiponectin levels and the risk of hypertension: a systematic review and meta-analysis,” Hypertension, vol. 62, no. 1, pp. 27–32, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. V. Fontana, A. P. d. Faria, G. H. Oliveira-Paula, P. S. Silva, J. E. Tanus-Santos, and H. Moreno, “Effects of angiotensin-converting enzyme inhibition on leptin and adiponectin levels in essential hypertension,” Basic & Clinical Pharmacology & Toxicology, vol. 114, no. 6, pp. 472–475, 2014. View at Publisher · View at Google Scholar · View at Scopus
  69. H. Zhang and X. Jin, “Relationship between serum adiponectin and osteoproteregin levels and coronary heart disease severity,” Genetics and Molecular Research, vol. 14, no. 3, pp. 11023–11029, 2015. View at Publisher · View at Google Scholar · View at Scopus
  70. M. T. Guagnano, M. Romano, A. Falco et al., “Leptin increase is associated with markers of the hemostatic system in obese healthy women,” Journal of Thrombosis and Haemostasis, vol. 1, no. 11, pp. 2330–2334, 2003. View at Google Scholar
  71. A. S. Shamsuzzaman, M. Winnicki, R. Wolk et al., “Independent association between plasma leptin and C-reactive protein in healthy humans,” Circulation, vol. 109, no. 18, pp. 2181–2185, 2004. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Coimbra, C. Catarino, and A. Santos-Silva, “The triad psoriasis–obesity–adipokine profile,” Journal of the European Academy of Dermatology and Venereology, vol. 30, no. 11, pp. 1876–1885, 2016. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Gerdes, S. Osadtschy, M. Rostami-Yazdi, N. Buhles, M. Weichenthal, and U. Mrowietz, “Leptin, adiponectin, visfastin and retinol-binding protein-4 – mediators of comorbidities in the patients with psoriasis?” Experimental Dermatology, vol. 21, no. 1, pp. 43–47, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. E. Cavusoglu, C. Ruwende, V. Chopra et al., “Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain,” European Heart Journal, vol. 27, no. 19, pp. 2300–2309, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. J. M. Dekker, T. Funahashi, G. Nijpels et al., “Prognostic value of adiponectin for cardiovascular disease and mortality,” The Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 4, pp. 1489–1496, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. T. R. Aprahamian and F. Sam, “Adiponectin in cardiovascular inflammation and obesity,” International Journal of Inflammation, vol. 2011, Article ID 376909, 8 pages, 2011. View at Publisher · View at Google Scholar
  77. A. Russolillo, S. Iervolino, R. Peluso et al., “Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management,” Rheumatology, vol. 52, no. 1, pp. 62–67, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. C. H. J. Choi and P. Cohen, “Adipose crosstalk with other cell types in health and disease,” Experimental Cell Research, vol. 17, 2017. View at Publisher · View at Google Scholar
  79. K. K. Koh, S. M. Park, and M. J. Quon, “Leptin and cardiovascular diseases: response to therapeutic interventions,” Circulation, vol. 117, no. 25, pp. 3238–3249, 2012. View at Publisher · View at Google Scholar · View at Scopus
  80. M. Scotece, J. Conde, R. Gómez et al., “Role of adipokines in atherosclerosis: interferences with cardiovascular complications in rheumatic diseases,” Mediators of Inflammation, vol. 2012, Article ID 125458, 14 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. R. Adya, B. K. Tan, and H. S. Randeva, “Differential effects of leptin and adiponectin in endothelia angiogenesis,” Journal of Diabetes Research, vol. 2015, Article ID 648239, 12 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  82. Y. J. Chen, C. Y. Wu, J. L. Shen et al., “Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome,” Archives of Dermatology, vol. 144, no. 12, pp. 1571–1575, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. Y. Wang, J. Chen, Y. Zhao, L. Geng, F. Song, and H. D. Chen, “Psoriasis is associated with increased levels of serum leptin,” The British Journal of Dermatology, vol. 158, no. 5, pp. 1134-1135, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. L. Woodward, I. Akoumianakis, and C. Antoniades, “Unravelling the adiponectin paradox: novel roles of adiponectin in the regulation of cardiovascular disease,” British Journal of Pharmacology, vol. 173, no. 19, pp. 1–14, 2016. View at Publisher · View at Google Scholar · View at Scopus
  85. M. A. Ruscica, A. Baragetti, A. L. Catapano, and G. D. Norata, “Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: gaps and open questions,” Nutrition, Metabolism, and Cardiovascular Diseases, vol. 27, no. 5, pp. 379–395, 2016. View at Publisher · View at Google Scholar
  86. R. K. Upadhyay, “Emerging risk biomarkers in cardiovascular diseases and disorders,” Journal of Lipids, vol. 2015, Article ID 971453, 50 pages, 2015. View at Publisher · View at Google Scholar
  87. L. Mallbris, F. Granath, A. Hamsten, and M. Stahle, “Psoriasis is associated with lipid abnormalities at the onset of skin disease,” Journal of the American Academy of Dermatology, vol. 54, no. 4, pp. 614–621, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. S. Uczniak, Z. A. Gerlicz, M. Kozłowska, and A. Kaszuba, “Presence of selected metabolic syndrome components in patients with psoriasis vulgaris,” Postepy Dermatologii I Alergologii, vol. 33, no. 2, pp. 114–119, 2016. View at Publisher · View at Google Scholar · View at Scopus
  89. B. S. Uyanik, Z. Ari, E. Onur, K. Gündüz, S. Tanülkü, and K. Durkan, “Serum lipids and apolipoprotein in patients with psoriasis,” Clinical Chemistry and Laboratory Medicine, vol. 40, no. 1, pp. 65–68, 2002. View at Publisher · View at Google Scholar · View at Scopus
  90. E. Matsuura, G. R. V. Hughes, and M. A. Khamashta, “Oxidation of LDL and its clinical implication,” Autoimmunity Reviews, vol. 7, no. 7, pp. 558–566, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. K. Kotani, H. Koibuchi, T. Yamada, and N. Taniguchi, “The effects of lifestyle modification on a new oxidized low-density lipoprotein marker, serum amyloid A-LDL, in subjects with primary lipid disorder,” Clinica Chimica Acta, vol. 409, no. 1-2, pp. 67–69, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. Y. I. Miller and J. Y. Shyy, “Context-dependent role of oxidized lipids and lipoproteins in inflammation,” Trends in Endocrinology and Metabolism, vol. 28, no. 2, pp. 143–152, 2017. View at Publisher · View at Google Scholar · View at Scopus
  93. L. R. Lopez, T. R. Buckner, B. L. Hurley, K. Kobayashi, and E. Matsuura, “Determination of oxidized low-density lipoproteins (ox-LDL) versus ox-LDL⁄β2GPI complexes for the assessment of autoimmune-mediated atherosclerosis,” Annals of the New York Academy of Sciences, vol. 1109, pp. 303–310, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. K. Kobayashi, M. Kishi, T. Atsumi et al., “Circulating oxidized LDL forms with beta-2 glycoprotein I: implication as an atherogenic autoantigen,” Journal of Lipid Research, vol. 44, no. 4, pp. 716–726, 2003. View at Publisher · View at Google Scholar · View at Scopus
  95. N. Bassi, A. Ghirardello, L. Iaccarino et al., “OxLDL/beta2GPI-anti-oxLDL/beta2GPI complex and atherosclerosis in SLE patients,” Autoimmunity Reviews, vol. 7, no. 1, pp. 52–58, 2007. View at Publisher · View at Google Scholar · View at Scopus
  96. N. S. Tekin, I. O. Tekin, F. Barut, and E. Y. Sipahi, “Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients,” Mediators of Inflammation, vol. 2007, Article ID 78454, 5 pages, 2007. View at Publisher · View at Google Scholar